1035450-70-4

Basic information

• Product Name: 4,5-dichloro-2-(3,4-dimethylphenyl)pyridazin-3(2H)-one
• CAS NO: 1035450-70-4
• Molecular Weight: 269.13
• Mol File: 1035450-70-4.mol

Chemical Properties

• CAS DataBase Reference: 4,5-dichloro-2-(3,4-dimethylphenyl)pyridazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-dichloro-2-(3,4-dimethylphenyl)pyridazin-3(2H)-one(1035450-70-4)
• EPA Substance Registry System: 4,5-dichloro-2-(3,4-dimethylphenyl)pyridazin-3(2H)-one(1035450-70-4)

Safety Data

• Hazardous Substances Data: 1035450-70-4(Hazardous Substances Data)

Upstream product

• 766-40-5 Mucochloric acid 
• 13636-53-8 3,4-dimethylphenylhydrazine 

Downstream Products

• 1415356-21-6 C₁₉H₁₇ClN₂O₃ 

Relevant articles and documents

Design, synthesis and SAR analysis of novel potent and selective small molecule antagonists of NPBWR1 (GPR7)

Novel small molecule antagonists of NPBWR1 (GPR7) are herein reported. A high-throughput screening (HTS) of the Molecular Libraries-Small Molecule Repository library identified 5-chloro-4-(4-methoxyphenoxy)-2-(p-tolyl) pyridazin-3(2H)-one as a NPBWR1 hit antagonist with micromolar activity. Design, synthesis and structure-activity relationships study of the HTS-derived hit led to the identification of 5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy) pyridazin-3(2H)-one lead molecule with submicromolar antagonist activity at the target receptor and high selectivity against a panel of therapeutically relevant off-target proteins. This lead molecule may provide a pharmacological tool to clarify the molecular basis of the in vivo physiological function and therapeutic utility of NPBWR1 in diverse disease areas including inflammatory pain and eating disorders.

PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS

The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.